What is the best approach to manage tremors associated with opiate (opioid) withdrawal?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Managing Tremors in Opioid Withdrawal

The best approach to manage tremors associated with opioid withdrawal is to use buprenorphine as first-line treatment due to its superior safety profile, higher completion rates, and less severe withdrawal symptoms compared to other options. 1

Assessment and Monitoring

  • Use the Clinical Opiate Withdrawal Scale (COWS) to quantify withdrawal severity:
    • COWS <8: Mild withdrawal - no buprenorphine indicated yet
    • COWS >8: Moderate to severe withdrawal - proceed with buprenorphine 1
  • Tremors are specifically assessed in the COWS scale:
    • 0 = no tremor
    • 1 = tremor can be felt but not observed
    • 2 = slight tremor observable
    • 4 = gross tremor or muscle twitching 2

First-Line Treatment: Buprenorphine

Dosing Protocol

  • Initial dose: 4-8 mg sublingually based on withdrawal severity
  • Reassess after 30-60 minutes
  • Administer additional doses at 2-hour intervals if withdrawal symptoms (including tremors) persist
  • Target stabilization dose: 16 mg daily for most patients 1

Timing Considerations

  • Confirm appropriate timing since last opioid use:
    • Short-acting opioids: >12 hours
    • Extended-release formulations: >24 hours
    • Methadone maintenance: >72 hours 1

Alternative Treatments

Clonidine

  • If buprenorphine is unavailable or contraindicated, clonidine is effective for managing autonomic symptoms including tremors 3, 4
  • Dosing: 0.1-0.3 mg orally every 6-8 hours, titrated to control symptoms
  • Monitor for hypotension and sedation 5
  • Studies show clonidine produces marked reduction of withdrawal symptoms but does not eliminate them completely 4

Methadone

  • Similar effectiveness to buprenorphine in managing withdrawal symptoms
  • Particularly useful for patients already on methadone maintenance
  • Caution: Outpatients should not be converted to methadone for weaning without special expertise due to complex pharmacokinetics and high lethality 1

Tapering Protocol

  • Standard taper: Reduce dose by 10% or less per week 1
  • For prolonged opioid therapy (≥1 year): Slower taper of 10% per month is better tolerated 2
  • Each new dose should be 90% of the previous dose rather than a straight-line taper 1
  • For patients who have taken opioids for less than 7 days: Can discontinue quickly without tapering
  • For patients with opioid exposure between 7-14 days: Can be weaned more quickly
  • For patients with opioid exposure >14 days: Need to follow a weaning protocol 2

Adjunctive Treatments for Tremors and Other Withdrawal Symptoms

  • Benzodiazepines: Can help with anxiety, muscle cramps, and tremors 1
  • Gabapentin: Has been used to decrease withdrawal symptoms 2
  • Dexmedetomidine: Another α2-adrenergic agonist option for managing withdrawal symptoms 2
  • Amantadine: When combined with clonidine, results in milder withdrawal symptoms compared to clonidine alone 6

Monitoring During Treatment

  • Monitor vital signs regularly, especially blood pressure and heart rate
  • Check orthostatic vital signs before ambulation
  • Hold doses for hypotension or bradycardia 1
  • Parents and care providers should carefully monitor for signs of withdrawal during opioid weaning 2

Common Pitfalls to Avoid

  1. Administering buprenorphine too early (before adequate withdrawal)
  2. Inadequate dosing for withdrawal symptom control
  3. Failing to recognize that pain itself may be a withdrawal symptom
  4. Converting outpatients to methadone without special expertise
  5. Not addressing drug interactions, particularly with benzodiazepines 1

Long-Term Considerations

  • Protracted withdrawal syndrome may occur months after opioid elimination
  • Symptoms include dysphoria, irritability, insomnia, and anhedonia
  • These symptoms should be expected, discussed with the patient, and treated 1
  • Provide overdose prevention education and dispense take-home naloxone kit 1

Buprenorphine has consistently demonstrated superiority over clonidine in alleviating most subjective and objective opiate withdrawal symptoms, including tremors, with fewer side effects 7.

References

Guideline

Opioid Withdrawal Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Buprenorphine in opiate withdrawal: a comparison with clonidine.

Journal of substance abuse treatment, 1993

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.